Antimicrobial & Metabolic Support

Methylene blue intravenous therapy

A slow intravenous infusion of pharmaceutical-grade methylene blue at a low, physician-set dose, given on our ward as one module of a plan for chronic infections and mitochondrial dysfunction. Outside its approved indication, methemoglobinemia, it is an individual treatment attempt decided with you after medical consultation.

Conceptual illustration of deep blue dye dispersing inside a clear glass vessel.
What it is

What methylene blue infusion is

St. George Hospital gives methylene blue (methylthioninium chloride) as a slow intravenous infusion at a low dose set by your physician, as one module of a plan for chronic infections and mitochondrial dysfunction. It belongs to our infusion and immune therapies and is never used on its own. Outside its approved indication it is an individual treatment attempt decided with the patient after medical consultation.

Methylene blue is one of the oldest drugs in use. It was synthesized in the late 19th century, was one of the first antimalarials, and is approved today for methemoglobinemia, a condition in which hemoglobin can no longer carry oxygen; it is also used in intensive care for ifosfamide neurotoxicity and refractory vasoplegic shock (Pushparajah Mak et al., Pediatr Emerg Care, 2021). It stands on the WHO List of Essential Medicines for the approved indication.

The reason it appears on an infusion ward for chronic illness is its behavior inside mitochondria. At low concentrations methylene blue accepts electrons from NADH and hands them to cytochrome c, bypassing complex I and complex III of the electron transport chain and raising complex IV activity, which in cell and animal models supports ATP production and lowers oxidative stress (Tucker et al., Mol Neurobiol, 2018). The dose matters: at low doses the molecule cycles as an antioxidant, at high doses it becomes a pro-oxidant, which is why we stay at the low end and never escalate on the day.

Who it is for

Which conditions it is used for

Our physicians consider methylene blue for a small group of patients, always after the work-up and always inside a broader plan. The decision rests on the laboratory, the medication list and the exclusions below, not on the diagnosis alone.

  • Chronic Lyme disease, as an adjunct during antimicrobial therapy and hyperthermia, on the basis of laboratory data on persister forms of Borrelia
  • Post-COVID and chronic fatigue with documented mitochondrial impairment in the metabolic work-up
  • Selected chronic infections that have not responded to standard therapy, decided case by case
  • Age-related cognitive complaints assessed in the longevity program, where the mitochondrial rationale applies
  • Methemoglobinemia, the approved indication, which is an emergency treatment rather than a program module

We do not infuse methylene blue in glucose-6-phosphate dehydrogenase (G6PD) deficiency, in pregnancy or while breastfeeding, in severe kidney impairment, or in known hypersensitivity. The most important exclusion is pharmacological: any serotonergic medication, including SSRIs, SNRIs, tricyclic antidepressants, MAO inhibitors, tramadol, lithium and St John's wort. The combination can cause serotonin syndrome, and a washout decided by your physician is required before the first dose.

How a session runs on our ward

  1. Before the first dose

    A G6PD test, kidney values and a blood count. The physician checks your medications line by line; an active serotonergic drug postpones the infusion.

  2. The drip

    30 to 60 minutes

    A slow drip in the treatment chair. Pulse and blood pressure are recorded, and a nurse checks on you; slowing the rate usually settles mild symptoms.

  3. Observation

    A short rest after the bag is empty. The first dose is lower; the schedule for the stay is set once it has been tolerated.

  4. The next day or two

    24 to 48 hours

    Blue or green urine, and sometimes faintly bluish skin or eyes for a day. Both are expected and clear on their own.

Evidence and safety, graded

The evidence is strong only for the approved indication, methemoglobinemia; for the uses on our ward it is emerging or limited. Pulse and blood pressure are recorded, and a nurse stays nearby during the drip.

Show studies, risks and side effects

The evidence is strong for the approved indication, methemoglobinemia, where methylene blue restores the oxygen-carrying form of hemoglobin within minutes. For everything we use it for on the ward the evidence is emerging or limited, and that is the honest frame for the decision.

Mitochondrial support is emerging evidence. The electron-shuttling mechanism and the effects on complex IV activity, oxidative stress and neuroinflammation are documented in cell and animal models of neurodegeneration and brain injury (Tucker et al., Mol Neurobiol, 2018); controlled trials in post-viral fatigue have not been published.

In Lyme disease the evidence is limited. A screen of an FDA-approved drug library at Johns Hopkins identified methylene blue among the compounds with activity against persister forms of Borrelia burgdorferi in culture (Feng et al., Antibiotics, 2015). That is a laboratory finding. Our use in the Lyme program rests on it and on clinical experience with 12,000+ Lyme patients since 1995, and it is an individual treatment attempt.

What the evidence does not show: that intravenous methylene blue clears Borrelia in people, or improves fatigue or cognition in a controlled trial outside the approved indications.

Safety rests on two screens. Methylene blue is a potent inhibitor of monoamine oxidase A; a review of reported cases of central nervous system toxicity found that 13 of 14 met the criteria for serotonin toxicity, precipitated by the combination with serotonin reuptake inhibitors, at intravenous doses as low as 1 mg per kilogram (Gillman, J Psychopharmacol, 2011). The second screen is G6PD deficiency, the most common human enzyme defect, in which oxidizing drugs can cause hemolysis; which medications are safe in that condition has been set out in an evidence-based review (Youngster et al., Drug Saf, 2010), and methylene blue is among those we do not give. Beyond these, side effects at our doses are the blue discolouration of urine and skin, occasional nausea or headache during the drip, and rarely a drop in blood pressure, which is why pulse and blood pressure are recorded and a nurse stays nearby.

Where we use it

How it fits your program

Methylene blue is a supporting module, usually scheduled in the second week once the work-up is complete and the medication review is done. In the Lyme program it runs alongside antimicrobial therapy, whole-body hyperthermia, ozone therapy and immune therapy with thymus peptides. Where fatigue and cognitive complaints dominate, our physicians combine it with NAD+ infusions, high-dose vitamin drips and hyperbaric oxygen therapy, spacing the infusions across the week so that no two run on the same day. The detoxification therapies frame the whole block.

We measure before the first dose and again in week two: the metabolic markers from the work-up, the fatigue questionnaire and, where cognition is the complaint, a short standardized test. Whether a component continues after you are home is decided from that comparison in the discharge letter, which your physician at home receives in English. The pattern of a stay, from admission day to discharge, is described on how a stay runs.

Costs

Costs and billing

You receive a written, itemized cost overview after a physician has read your findings and before anything is booked. Costs are a package price plus individual add-ons, and a deposit is paid before admission; methylene blue infusions appear as one block within the infusion therapies. Treatment is self-pay, and the invoice is itemized in English with diagnoses and procedure descriptions for out-of-network review. Details are on costs and insurance; the path from first email to arrival from Munich Airport is on information for international patients.

Questions

Questions patients ask

Is methylene blue an approved treatment for Lyme disease or fatigue?

No. Methylene blue is approved for methemoglobinemia and used in hospitals for a few other acute indications. Its use for chronic infections, fatigue or cognitive complaints is an individual treatment attempt decided with you after medical consultation. The laboratory evidence is interesting; controlled trials in these conditions have not been published, and your physician tells you this before you decide.

Which medications rule it out?

Any drug that raises serotonin: SSRIs and SNRIs, tricyclic antidepressants, MAO inhibitors, tramadol, lithium, St John's wort and some migraine and anti-nausea drugs. Methylene blue inhibits monoamine oxidase A and can trigger serotonin syndrome with these. We go through your medication list line by line before the first dose and do not infuse while such a drug is active.

Why do you test for G6PD deficiency first?

Methylene blue is an oxidizing dye. In people with glucose-6-phosphate dehydrogenase deficiency, an inherited enzyme defect carried by an estimated 400 million people, oxidizing drugs can break down red blood cells. A simple blood test on the first day of your stay rules the deficiency in or out; with a positive result the infusion is not given.

What will I notice after the infusion?

Your urine is blue or green for 24 to 48 hours, and the skin or the whites of the eyes can look faintly bluish for a day. Both are expected and clear on their own. At the low doses we use, nausea or a headache during the drip are uncommon and settle when the rate is slowed. Tell the nurse at once about chest tightness or restlessness.

How much does methylene blue therapy cost?

Methylene blue infusions appear as a therapy block in the written, itemized cost overview that you receive after a physician has read your findings. The written cost overview shows the package price plus the individual add-ons your plan needs. Treatment is self-pay; the invoice is written in English for out-of-network review.

Write to the International Office with a short history; it requests your findings and your current medication list afterwards. A physician reads them before the video consultation and tells you whether methylene blue belongs in your plan.

References

  1. Methylene blue: an antidote for methemoglobinemia and beyond. Pediatr Emerg Care 2021. PMID 34463662
  2. From mitochondrial function to neuroprotection: an emerging role for methylene blue. Mol Neurobiol 2018. PMID 28840449
  3. Identification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug library. Antibiotics (Basel) 2015. PMID 27025631
  4. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol 2011. PMID 20142303
  5. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010. PMID 20701405

Send a free inquiry

The initial inquiry is free of charge. The International Office reviews your message and your case directly and gets back to you.

Hours
Mon–Thu 08:00–17:00, Fri 08:00–14:00 German time (CET/CEST); in the US Mon–Thu 2–11 a.m. ET, Fri 2–8 a.m. ET.

Munich Airport (MUC), about 60 minutes by car.

CallSend a free inquiry